Literature DB >> 6267246

The inhibitory effect of propranolol pretreatment on its own metabolism in the rat.

D W Schneck, J F Pritchard.   

Abstract

Repetitive oral administration of propranolol to rats (100 mg/kg/day for 5 days) resulted in a marked inhibition of hepatic microsomal metabolism of propranolol when incubated at low initial substrate concentrations (less than 2 microM). Associated with the inhibition of propranolol metabolism was a significant reduction in metabolites derived from naphthalene ring oxidation and an increased formation of N-desisopropylpropranolol. In vivo studies after propranolol pretreatment resulted in: an increased hepatic concentration and an increased systemic availability of propranolol; a decreased hepatic and plasma concentration of polar metabolites; and an increased plasma concentration of metabolites derived from propranolol N-dealkylation. Propranolol was converted both in vitro and in vivo by a hepatic microsomal mixed-function oxidase to a reactive metabolite capable of covalently binding with microsomal macromolecules. We propose that selective covalent binding of the reactive intermediate to the molecular form of cytochrome P-450 that ring hydroxylates propranolol would account for the marked inhibition of propranolol metabolism in vitro and for the increased systemic availability of propranolol in vivo after pretreatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6267246

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  The effect of a single treatment with cigarette smoke on the blood levels and hemodynamic effects of propranolol in rats.

Authors:  T Berkan; L Ustünes; Z Kerry; M Karol; M Tosun; C Yalçinkaya; A Ozer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jul-Sep       Impact factor: 2.441

2.  The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.

Authors:  J C McCourty; J H Silas; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

3.  Partial metabolic clearances as determinants of the oral bioavailability of propranolol.

Authors:  T Walle; U K Walle; L S Olanoff; E C Conradi
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

4.  Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.

Authors:  G T Tucker; N D Bax; M S Lennard; S Al-Asady; H S Bharaj; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

5.  Proceedings of the British Pharmacological Society 8th-10th September, 1982. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1982-12       Impact factor: 8.739

6.  Propranolol does not alter flutoprazepam kinetics and metabolism in the rat.

Authors:  I Conti; S Sarati; S Caccia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

7.  Diazepam/beta-adrenoceptor antagonist interactions.

Authors:  G Hawksworth; T Betts; A Crowe; R Knight; I Nyemitei-Addo; K Parry; J C Petrie; A Raffle; A Parsons
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

8.  Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in man.

Authors:  N D Bax; R W Jones; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

9.  Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.

Authors:  K Rowland; W W Yeo; S W Ellis; I G Chadwick; I Haq; M S Lennard; P R Jackson; L E Ramsay; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

10.  Effect of hepatic and renal dysfunction on disposition of bupropion in rats.

Authors:  J S Kaka; K I Al-Khamis; M O Tanira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Jul-Sep       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.